Vascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in mice

Neoplasia

Volumn 13, Issue 3, 2011, Pages 244-253

  Edrei, Yifat ^a   Gross, Eitan ^a   Corchia, Nathalie ^a   Tsarfaty, Galia ^b   Galun, Eithan ^a   Pappo, Orit ^a   Abramovitch, Rinat ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTERIAL BLOOD; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SIZE; COLORECTAL ADENOCARCINOMA; COLORECTAL CARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; HEMODYNAMIC RESPONSE IMAGING; HEMODYNAMICS; HISTOPATHOLOGY; INTERMETHOD COMPARISON; LIVER METASTASIS; LIVER PERFUSION; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY TUMOR; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TUMOR VASCULARIZATION;

EID: 79952381691     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101354     Document Type: Article

References (51)

1. El-Serag HB and Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576.
2. Llovet JM and Bruix J (2008). Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1), S20-S37.
3. Baker ME and Pelley R (1995). Hepatic metastases: basic principles and implications for radiologists. Radiology 197, 329-337.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
5. McLoughlin JM, Jensen EH, and Malafa M (2006). Resection of colorectal liver metastases: current perspectives. Cancer Control 13, 32-41.
6. El-Serag HB, Marrero JA, Rudolph L, and Reddy KR (2008). Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134, 1752-1763.
7. Finlay IG and McArdle CS (1983). Effect of occult hepatic metastases on survival after curative resection for colorectal carcinoma. Gastroenterology 85, 596-599.
8. Rothbarth J and van de Velde CJ (2005). Treatment of liver metastases of colorectal cancer. Ann Oncol 16(Suppl 2), ii144-ii149.
9. Ruers T and Bleichrodt RP (2002). Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 38, 1023-1033.
10. Vogl TJ, Zangos S, Eichler K, Yakoub D, and Nabil M (2007). Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 17, 1025-1034.
11. Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, Djonov V, Stoupis C, and Dufour JF (2007). Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46, 840-848.
12. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, et al. (2002). Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8, 128-135.
13. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, and Suthanthiran M (2003). Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 63, 917-926.
14. HojoM,Morimoto T,Maluccio M, Asano T,Morimoto K, Lagman M, Shimbo T, and Suthanthiran M (1999). Cyclosporine induces cancer progression by a cellautonomous mechanism. Nature 397, 530-534.
15. Luan FL, Hojo M, Maluccio M, Yamaji K, and Suthanthiran M (2002). Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73, 1565-1572.
16. Brindle K (2008). New approaches for imaging tumour responses to treatment. Nat Rev Cancer 8, 94-107.
17. Michaelis LC and Ratain MJ (2006). Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 6, 409-414.
18. Miller JC, Pien HH, Sahani D, Sorensen AG, and Thrall JH (2005). Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 97, 172-187.
19. Checkley D, Tessier JJ, Kendrew J, Waterton JC, and Wedge SR (2003). Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89, 1889-1895.
20. Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J, et al. (2002). PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62, 4015-4022.
21. Evelhoch JL, LoRusso PM,He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, et al. (2004). Magnetic resonance imaging measurements of the response of murine and human tumors to the vasculartargeting agent ZD6126. Clin Cancer Res 10, 3650-3657.
22. Fuh G,Wu P, LiangWC, Ultsch M, Lee CV, Moffat B, and Wiesmann C (2006). Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 281, 6625-6631.
23. Mross K, Drevs J, Muller M, Medinger M, Marme D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, et al. (2005). Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 41, 1291-1299.
24. Barrett T, Brechbiel M, Bernardo M, and Choyke PL (2007). MRI of tumor angiogenesis. J Magn Reson Imaging 26, 235-249.
25. Leach MO,Brindle KM,Evelhoch JL,Griffiths JR,Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, et al. (2005). The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92, 1599-1610.
26. Breedis C and Young G (1954). The blood supply of neoplasms in the liver. Am J Pathol 30, 969-977.
27. Pandharipande PV, Krinsky GA, Rusinek H, and Lee VS (2005). Perfusion imaging of the liver: current challenges and future goals. Radiology 234, 661-673.
28. Leveson SH, Wiggins PA, Giles GR, Parkin A, and Robinson PJ (1985). Deranged liver blood flow patterns in the detection of liver metastases. Br J Surg 72, 128-130.
29. Leen E, Goldberg JA, Angerson WJ, and McArdle CS (2000). Potential role of Doppler perfusion index in selection of patients with colorectal cancer for adjuvant chemotherapy. Lancet 355, 34-37.
30. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, and Rodes J (2001). Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35, 421-430.
31. Bruix J and Sherman M (2005). Management of hepatocellular carcinoma. Hepatology 42, 1208-1236.
32. Coenegrachts K, Ghekiere J, Denolin V, Gabriele B, Herigault G, Haspeslagh M, Daled P, Bipat S, Stoker J, and Rigauts H (2010). Perfusion maps of the whole liver based on high temporal and spatial resolution contrast-enhanced MRI (4D THRIVE): feasibility and initial results in focal liver lesions. Eur J Radiol 74, 529-535.
33. Barash H, Gross E, Matot I, Edrei Y, Tsarfaty G, Spira G, Vlodavsky I, Galun E, and Abramovitch R (2007). Functional MR imaging during hypercapnia and hyperoxia: noninvasive tool for monitoring changes in liver perfusion and hemodynamics in a rat model. Radiology 243, 727-735.
34. Barash H, Gross E, Edrei Y, Pappo O, Spira G, Vlodavsky I, Galun E, Matot I, and Abramovitch R (2008). Functional magnetic resonance imaging monitoring of pathological changes in rodent livers during hyperoxia and hypercapnia. Hepatology 48, 1232-1241.
35. Matot I, Cohen K, Pappo O, Barash H, and Abramovitch R (2008). Liver response to hemorrhagic shock and subsequent resuscitation:MRI analysis. Shock 29, 16-24.
36. Kollmar O, Schilling MK, and Menger MD (2004). Experimental liver metastasis: standards for local cell implantation to study isolated tumor growth in mice. Clin Exp Metastasis 21, 453-460.
37. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, van den Bergh Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RP, et al. (1994). Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 145, 1237-1245.
38. Robinson PJ (2000). Imaging liver metastases: current limitations and future prospects. Br J Radiol 73, 234-241.
39. Blyth S, Blakeborough A, Peterson M, Cameron IC, and Majeed AW (2008). Sensitivity of magnetic resonance imaging in the detection of colorectal liver metastases. Ann R Coll Surg Engl 90, 25-28.
40. Abramovitch R, Frenkiel D, and Neeman M (1998). Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging. Magn Reson Med 39, 813-824.
41. Leen E (1999). The detection of occult liver metastases of colorectal carcinoma. J Hepatobiliary Pancreat Surg 6, 7-15.
42. Liu Y and Matsui O (2007). Changes of intratumoral microvessels and blood perfusion during establishment of hepatic metastases in mice. Radiology 243, 386-395.
43. Dezso K, Bugyik E, Papp V, Laszlo V, Dome B, Tovari J, Timar J, Nagy P, and Paku S (2009). Development of arterial blood supply in experimental liver metastases. Am J Pathol 175, 835-843.
44. ten Dam MA and Wetzels JF (2008). Toxicity of contrast media: an update. Neth J Med 66, 416-422.
45. Freiman M, Edrei Y, Sela Y, Shmidmayer Y,Gross E, Joskowicz L, and Abramovitch R (2008). Classification of suspected liver metastases using fMRI images: a machine learning approach. Med Image Comput Comput Assist Interv 11, 93-100.
46. Song R, Cohen AR, and Song HK (2007). Improved transverse relaxation rate measurement techniques for the assessment of hepatic and myocardial iron content. J Magn Reson Imaging 26, 208-214.
47. White MJ, Hawkes DJ, Melbourne A, Collins DJ, Coolens C, Hawkins M, Leach MO, and Atkinson D (2009). Motion artifact correction in free-breathing abdominal MRI using overlapping partial samples to recover image deformations. Magn Reson Med 62, 440-449.
48. Jin N, Deng J, Chadashvili T, Zhang Y, Guo Y, Zhang Z, Yang GY, Omary RA, and Larson AC (2010). Carbogen gas-challenge BOLD MR imaging in a rat model of diethylnitrosamine-induced liver fibrosis. Radiology 254, 129-137.
49. Song R, Cohen AR, and Song HK (2007). Improved transverse relaxation rate measurement techniques for the assessment of hepatic and myocardial iron content. J Magn Reson Imaging 26, 208-214.
50. Jin N, Deng J, Chadashvili T, Zhang Y, Guo Y, Zhang Z, Yang GY, Omary RA, and Larson AC (2010). Carbogen gas-challenge BOLD MR imaging in a rat model of diethylnitrosamine-induced liver fibrosis. Radiology 254, 129-137.
51. Freiman M, Edrei Y, Sela Y, Shmidmayer Y, Gross E, Joskowicz L, and Abramovitch R (2008). Classification of suspected liver metastases using fMRI images: a machine learning approach. Med Image Comput Comput Assist Interv 11, 93-100.